Drugs / Livoletide
Livoletide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT03790865 | Mar 2019 → Feb 2020 | Prader-Willi syndrome | Millendo Therapeutics SAS | Terminated | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02040012 Comparator | Jul 2013 → Oct 2015 | type 2 diabetes mellitus | Alizé Pharma | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Livoletide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03790865 ↗ |
| Known as | AZP531 | “A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus” NCT02040012 ↗ |
| Known as | Livoletida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2029605 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2029605 ↗ |
| Route | Subcutaneous | “subcut administration once or twice daily” NCT02040012 ↗ |